ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 84 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2014. The put-call ratio across all filers is 0.72 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $751,000 | -9.7% | 59,959 | -0.2% | 0.00% | 0.0% |
| Q3 2016 | $832,000 | +39.8% | 60,094 | -0.2% | 0.00% | 0.0% |
| Q2 2016 | $595,000 | -22.1% | 60,234 | +33.3% | 0.00% | 0.0% |
| Q1 2016 | $764,000 | -22.3% | 45,178 | +2.3% | 0.00% | 0.0% |
| Q4 2015 | $983,000 | -5.0% | 44,173 | +0.6% | 0.00% | 0.0% |
| Q3 2015 | $1,035,000 | -71.6% | 43,888 | -1.5% | 0.00% | -80.0% |
| Q2 2015 | $3,644,000 | +102.1% | 44,571 | +128.9% | 0.01% | +150.0% |
| Q1 2015 | $1,803,000 | +160.5% | 19,468 | +13.8% | 0.00% | +100.0% |
| Q4 2014 | $692,000 | +112.3% | 17,106 | +28.4% | 0.00% | – |
| Q3 2014 | $326,000 | +53.1% | 13,323 | -0.9% | 0.00% | – |
| Q2 2014 | $213,000 | +5.4% | 13,447 | +0.5% | 0.00% | – |
| Q1 2014 | $202,000 | +18.1% | 13,378 | +7.7% | 0.00% | – |
| Q4 2013 | $171,000 | -22.3% | 12,420 | +6.5% | 0.00% | – |
| Q3 2013 | $220,000 | – | 11,664 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
| Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
| Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
| Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
| SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
| Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
| CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
| Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |